These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Comparative persistence and adherence to overactive bladder medications in patients with and without diabetes. Johnston S; Janning SW; Haas GP; Wilson KL; Smith DM; Reckard G; Quan SP; Bukofzer S Int J Clin Pract; 2012 Nov; 66(11):1042-51. PubMed ID: 23067028 [TBL] [Abstract][Full Text] [Related]
5. A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain. Nazir J; Hakimi Z; Guelfucci F; Khemiri A; Fatoye F; Blázquez AMM; González MH BMC Urol; 2018 Sep; 18(1):76. PubMed ID: 30180826 [TBL] [Abstract][Full Text] [Related]
6. Prospective Pilot Study of Mirabegron in Pediatric Patients with Overactive Bladder. Blais AS; Nadeau G; Moore K; Genois L; Bolduc S Eur Urol; 2016 Jul; 70(1):9-13. PubMed ID: 26876327 [TBL] [Abstract][Full Text] [Related]
7. Presence of central nervous system, cardiovascular and overall co-morbidity burden in patients with overactive bladder disorder in a real-world setting. Asche CV; Kim J; Kulkarni AS; Chakravarti P; Andersson KE BJU Int; 2012 Feb; 109(4):572-80. PubMed ID: 21777361 [TBL] [Abstract][Full Text] [Related]
8. Antimuscarinic Use in Females With Overactive Bladder Syndrome Increases the Risk of Depressive Disorder: A 3-Year Follow-up Study. Chung SD; Weng SS; Huang CY; Lin HC; Kao LT J Clin Pharmacol; 2017 Aug; 57(8):1064-1070. PubMed ID: 28378881 [TBL] [Abstract][Full Text] [Related]
9. Baseline Brain Segmental Volumes in Responders and Nonresponders to Anticholinergic Therapy for Overactive Bladder Syndrome. Sheyn D; Martin NM; Walden L; Roberts KM; El-Nashar S; Hijaz AK; Prescott JW Female Pelvic Med Reconstr Surg; 2021 Feb; 27(2):e399-e407. PubMed ID: 32925424 [TBL] [Abstract][Full Text] [Related]
10. The concomitant use of fesoterodine and topical vaginal estrogen in the management of overactive bladder and sexual dysfunction in postmenopausal women. Chughtai B; Forde JC; Buck J; Asfaw T; Lee R; Te AE; Kaplan SA Post Reprod Health; 2016 Mar; 22(1):34-40. PubMed ID: 26883688 [TBL] [Abstract][Full Text] [Related]
11. Use of desipramine for the treatment of overactive bladder refractory to antimuscarinic therapy. Hillelsohn JH; Rais-Bahrami S; Bagadiya N; Kashan M; Weiss GH Urol J; 2014 Jan; 10(4):1114-8. PubMed ID: 24469659 [TBL] [Abstract][Full Text] [Related]
12. Long-term patterns of use and treatment failure with anticholinergic agents for overactive bladder. Chancellor MB; Migliaccio-Walle K; Bramley TJ; Chaudhari SL; Corbell C; Globe D Clin Ther; 2013 Nov; 35(11):1744-51. PubMed ID: 24091072 [TBL] [Abstract][Full Text] [Related]
14. No Increased Risk of Fracture in Patients Receiving Antimuscarinics for Overactive Bladder Syndrome: A Retrospective Cohort Study. Kao LT; Huang CY; Lin HC; Chu CM J Clin Pharmacol; 2018 Jun; 58(6):727-732. PubMed ID: 29315618 [TBL] [Abstract][Full Text] [Related]
16. Healthcare resource use and costs of privately insured patients who switch, discontinue, or persist on anti-muscarinic therapy for overactive bladder. Ivanova JI; Hayes-Larson E; Sorg RA; Birnbaum HG; Berner T J Med Econ; 2014 Oct; 17(10):741-50. PubMed ID: 25051328 [TBL] [Abstract][Full Text] [Related]
17. Antimuscarinic Medication Use in Elderly Patients with Overactive Bladder. Kachru N; Sura S; Chatterjee S; Aparasu RR Drugs Aging; 2016 Oct; 33(10):755-763. PubMed ID: 27681701 [TBL] [Abstract][Full Text] [Related]
18. Effect of Potentially Inappropriate Use of Antimuscarinic Medications on Healthcare Use and Cost in Individuals with Overactive Bladder. Suehs BT; Davis C; Franks B; Yuran TE; Ng D; Bradt J; Knispel J; Vassilakis M; Berner T J Am Geriatr Soc; 2016 Apr; 64(4):779-87. PubMed ID: 27059714 [TBL] [Abstract][Full Text] [Related]
19. Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy. Liu HT; Lin H; Kuo HC Neurourol Urodyn; 2011 Nov; 30(8):1525-9. PubMed ID: 21826717 [TBL] [Abstract][Full Text] [Related]
20. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]